Aarhus University Seal / Aarhus Universitets segl

Elevated vitamin B12 levels and cancer risk in UK primary care: a THIN database cohort study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Elevated vitamin B12 levels and cancer risk in UK primary care : a THIN database cohort study. / Arendt, Johan F; Sorensen, Henrik Toft; Horsfall, Laura J; Petersen, Irene.

In: Cancer Epidemiology, Biomarkers & Prevention, Vol. 28, No. 4, 04.2019, p. 814-821.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Arendt, Johan F ; Sorensen, Henrik Toft ; Horsfall, Laura J ; Petersen, Irene. / Elevated vitamin B12 levels and cancer risk in UK primary care : a THIN database cohort study. In: Cancer Epidemiology, Biomarkers & Prevention. 2019 ; Vol. 28, No. 4. pp. 814-821.

Bibtex

@article{8c283866598b49498c2927afdc981b4c,
title = "Elevated vitamin B12 levels and cancer risk in UK primary care: a THIN database cohort study",
abstract = "Background: Elevated vitamin B12 levels (B12) are associated with increased short-term cancer risk. However, the implications for early cancer detection in primary care have not been assessed. Methods: Individuals with plasma B12 measurements were sampled from The Health Improvement Network primary care database, UK. Persons with low B12 levels were excluded together with persons with cancer or B12 treatment before date of B12 measurement. Incident cancer was the outcome of interest and was identified through Read codes. Individuals were disaggregated according to plasma B12 levels (unit: pmol/L): 150–600 (reference range values), 601–800, 801–1,000, and >1,000. Results: Among the 757,185 persons who met the inclusion criteria, we identified 33,367 incident cancers during 2,874,059 years of follow-up. We found a higher 1-year cancer risk among the 25,783 (3.4{\%}) persons with elevated B12 levels compared with those with normal B12 levels. After multivariable adjustment for lifestyle factors and social deprivation, persons with B12 >1,000 pmol/L had a 1-year incidence rate ratio of 4.72 (95{\%} confidence interval: 3.99–5.58). The association showed a nonlinear dose–response pattern, and it remained robust in stratified analyses, including when reducing the risk of confounding by indication in subanalyses. The risks were particularly elevated for liver cancer, pancreas cancer, and myeloid malignancies among persons with elevated B12 levels. Conclusions: Elevated plasma B12 levels were associated with a higher 1-year cancer risk than normal B12 levels among persons seen in UK primary care, suggesting that some cancers may affect B12 metabolism. Impact: Elevated B12 may mark occult cancer.",
author = "Arendt, {Johan F} and Sorensen, {Henrik Toft} and Horsfall, {Laura J} and Irene Petersen",
note = "{\circledC}2019 American Association for Cancer Research.",
year = "2019",
month = "4",
doi = "10.1158/1055-9965.EPI-17-1136",
language = "English",
volume = "28",
pages = "814--821",
journal = "Cancer Epidemiology, Biomarkers & Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research (A A C R)",
number = "4",

}

RIS

TY - JOUR

T1 - Elevated vitamin B12 levels and cancer risk in UK primary care

T2 - a THIN database cohort study

AU - Arendt, Johan F

AU - Sorensen, Henrik Toft

AU - Horsfall, Laura J

AU - Petersen, Irene

N1 - ©2019 American Association for Cancer Research.

PY - 2019/4

Y1 - 2019/4

N2 - Background: Elevated vitamin B12 levels (B12) are associated with increased short-term cancer risk. However, the implications for early cancer detection in primary care have not been assessed. Methods: Individuals with plasma B12 measurements were sampled from The Health Improvement Network primary care database, UK. Persons with low B12 levels were excluded together with persons with cancer or B12 treatment before date of B12 measurement. Incident cancer was the outcome of interest and was identified through Read codes. Individuals were disaggregated according to plasma B12 levels (unit: pmol/L): 150–600 (reference range values), 601–800, 801–1,000, and >1,000. Results: Among the 757,185 persons who met the inclusion criteria, we identified 33,367 incident cancers during 2,874,059 years of follow-up. We found a higher 1-year cancer risk among the 25,783 (3.4%) persons with elevated B12 levels compared with those with normal B12 levels. After multivariable adjustment for lifestyle factors and social deprivation, persons with B12 >1,000 pmol/L had a 1-year incidence rate ratio of 4.72 (95% confidence interval: 3.99–5.58). The association showed a nonlinear dose–response pattern, and it remained robust in stratified analyses, including when reducing the risk of confounding by indication in subanalyses. The risks were particularly elevated for liver cancer, pancreas cancer, and myeloid malignancies among persons with elevated B12 levels. Conclusions: Elevated plasma B12 levels were associated with a higher 1-year cancer risk than normal B12 levels among persons seen in UK primary care, suggesting that some cancers may affect B12 metabolism. Impact: Elevated B12 may mark occult cancer.

AB - Background: Elevated vitamin B12 levels (B12) are associated with increased short-term cancer risk. However, the implications for early cancer detection in primary care have not been assessed. Methods: Individuals with plasma B12 measurements were sampled from The Health Improvement Network primary care database, UK. Persons with low B12 levels were excluded together with persons with cancer or B12 treatment before date of B12 measurement. Incident cancer was the outcome of interest and was identified through Read codes. Individuals were disaggregated according to plasma B12 levels (unit: pmol/L): 150–600 (reference range values), 601–800, 801–1,000, and >1,000. Results: Among the 757,185 persons who met the inclusion criteria, we identified 33,367 incident cancers during 2,874,059 years of follow-up. We found a higher 1-year cancer risk among the 25,783 (3.4%) persons with elevated B12 levels compared with those with normal B12 levels. After multivariable adjustment for lifestyle factors and social deprivation, persons with B12 >1,000 pmol/L had a 1-year incidence rate ratio of 4.72 (95% confidence interval: 3.99–5.58). The association showed a nonlinear dose–response pattern, and it remained robust in stratified analyses, including when reducing the risk of confounding by indication in subanalyses. The risks were particularly elevated for liver cancer, pancreas cancer, and myeloid malignancies among persons with elevated B12 levels. Conclusions: Elevated plasma B12 levels were associated with a higher 1-year cancer risk than normal B12 levels among persons seen in UK primary care, suggesting that some cancers may affect B12 metabolism. Impact: Elevated B12 may mark occult cancer.

U2 - 10.1158/1055-9965.EPI-17-1136

DO - 10.1158/1055-9965.EPI-17-1136

M3 - Journal article

VL - 28

SP - 814

EP - 821

JO - Cancer Epidemiology, Biomarkers & Prevention

JF - Cancer Epidemiology, Biomarkers & Prevention

SN - 1055-9965

IS - 4

ER -